NCT04006093

Apixaban in Subjects With Peritoneal Dialysis

Pharmacokinetics of Apixaban in Subjects With End-stage Renal Disease Treated With Peritoneal Dialysis: the ApiDP Study

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: University Hospital, Caen · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to assess the pharmacokinetics of a single oral dose of apixaban (5mg) in participants with dialysis peritoneal versus participants with normal renal function.

Detailed description

Participants with chronic renal disease treated with peritoneal dialysis and participants with normal renal function are hospitalized for three days.

Conditions

• Chronic Renal Insufficiency
• Peritoneal Dialysis

Interventions

Type	Name	Description
DRUG	Apixaban single dose 5mg	Apixaban oral single dose 5mg

Timeline

• Start date: 2019-12-08
• Primary completion: 2022-12-10
• Completion: 2022-12-10
• First posted: 2019-07-02
• Last updated: 2026-03-27

Locations

1 site across 1 country: France